Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/151898
Title: Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project
Author: Calderon, M. A.
Demoly, Pascal
Casale, T.
Akdis, C. A.
Bachert, C.
Bewick, M.
Bilò, B. M.
Bohle, B.
Bonini, S.
Bush, A.
Caimmi, D. P.
Canonica, G. W.
Cardona, V.
Chiriac, A. M.
Cox, L.
Custovic, A.
Blay, F. De
Devillier, P.
Didier, A.
Lorenzo, G. Di
Toit, G. Du
Durham, S. R.
Eng, P.
Fiocchi, A.
Fox, A. T.
Gerth van Wijk, R.
Gomez, R. M.
Haathela, T.
Halken, S.
Hellings, P. W.
Jacobsen, L.
Just, J.
Tanno, L. K.
Kleine‑Tebbe, J.
Klimek, Ludger
Knol, E. F.
Kuna, P.
Larenas‑Linnemann, D. E.
Linneberg, Allan
Matricardi, M.
Malling, H. J.
Moesges, R.
Mullol i Miret, Joaquim
Muraro, A.
Papadopoulos, N. G.
Passalacqua, Giovanni
Pastorello, E.
Pfaar, Oliver
Price, David B.
Rodriguez del Rio, P.
Ruëff, R.
Samolinski, B.
Scadding, Glenis
Senti, G.
Shamji, M. H.
Sheikh, A.
Sisul, J. C.
Sole, D.
Sturm, G. J.
Tabar, A.
Van Ree, R.
Ventura, M. T.
Vidal, C.
Varga, E. M.
Worm, M.
Zuberbier, T.
Bousquet, J.
Keywords: Al·lèrgia
Immunoteràpia
Allergy
Immunotherapy
Issue Date: 23-Nov-2016
Publisher: BioMed Central
Abstract: Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s13601-016-0131-x
It is part of: Clinical and Translational Allergy, 2016, vol. 6
URI: http://hdl.handle.net/2445/151898
Related resource: https://doi.org/10.1186/s13601-016-0131-x
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)



This item is licensed under a Creative Commons License Creative Commons